Expresscells 20logo


Creating custom knock-in cell lines for biological research up to 75% faster than competitive technologies

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded September 2018
  • Employees 6
  • Incorporation Type C-corp
  • Website

Company Summary

ExpressCells creates custom and catalog knock-in cell lines for biological research. Our approach uses CRISPR plus our patent-pending plasmid system to create pure cell lines in as little as 25% of the time compared to older approaches. Our living cells replicate diseases or have proteins glow in multiple colors, speeding drug development. We are commercializing via multi-channel marketing (e-commerce, online promotion, representatives.


  • Matt Handel has over 25 years in life sciences. A graduate of Princeton and MIT, Matt has worked in product development, business development, and commercial roles at both Merck and Shire. He is an experienced fund-raiser, operations lead, and sits on several Boards. This is his third start-up.

  • Fullsizerender
    Founder and Scientific Advisor

    Oscar Perez Leal, MD, has been at Temple University for 15 years, where he conducts research on biochemistry and molecular biology. Oscar is currently a professor in the School of Pharmacy and is an inventor on multiple patents, including ExpressCells’ technology. He has both medical and business degrees.

  • 13883962 1055 47d2 87f2 7ac35c6ceb71
    Commercial Lead

    David Becker, MD, has provided consulting, communication, and strategic guidance to pharma and biotech companies for over 20 years. As President of the Exeter Group, he sold services into leading life sciences companies and worked with senior executives. David has taken a lead in developing the commercial approaches for ExpressCells. A trained physician, he is a graduate of Yale, NYU Medical School, and the Sloan School at MIT.

  • Bef1fe2e a66b 4d38 8611 82bbe44ed11e
    Controller & Financial Advisor

    Connie Davies has a broad background in finance covering many industries. She is Principal of CD Advisory Services, LLC serving startups and development companies in life science. An alumna from Shire, Connie has worked with SaaS and consultancy firms, IT customized technology management, and biotech development companies. She brings a critical eye and optimized approach in business planning and execution.

  • 07898e9c 0be4 4e8e abec 74b379e5ef0a
    Board Director

    Principal, TreD Avon Advisors, LLC. & Interim CEO, SwanBio Therapeutics. Chief Commercial Strategy Officer of Sage Therapeutics, Inc. from 2014 to 2019. Between 2004 and 2014, senior operating (P&L) executive with Shire Pharmaceuticals Group. Prior to that, Tom was with J&J. Between 2000 and 2002, Tom served in C-suite roles as part of Claneil Enterprises, Inc. Earned an MBA from Notre Dame and a BS in civil engineering from Lehigh University.